Research programme: apoptosis inducers - EpiCept Corporation

Drug Profile

Research programme: apoptosis inducers - EpiCept Corporation

Alternative Names: CV 2116; CV 43468; CV 55510; CV 58211; EP128504; EP129168; EP2161; EP95615; EPC 2167; Gambogic acid; MX 128504; MX 2060; MX 2167; MX 59003; MX 63844; MX 69501; MX 72086; MX 73883; MX 73936; MX 74420; MX 76629; MX 77356

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc
  • Class Fluorenes; Nicotinic-acids; Pyrimidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Caspase stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 20 Aug 2013 EpiCept Corporation has been acquired by Immune Pharmaceuticals Ltd
  • 26 Mar 2009 In vitro data presented at the 237th American Chemical Society National Meeting (ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top